

Flumatinib (mesylate)

Catalog No: tcsc1826



Available Sizes

Size: 500mg



Specifications

CAS No:

895519-91-2

Formula:

$C_{30}H_{33}F_3N_8O_4S$

Pathway:

Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

Target:

Bcr-Abl;PDGFR;c-Kit

Purity / Grade:

>98%

Solubility:

DMSO : 50 mg/mL (75.91 mM; Need ultrasonic); H₂O : 50 mg/mL (75.91 mM; Need ultrasonic)

Alternative Names:

HHGV678 mesylate

Observed Molecular Weight:

658.69

Product Description


Flumatinib mesylate (HH-GV-678 mesylate), a derivative of imatinib, is a multi-kinase inhibitor with IC₅₀ Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFR β and c-Kit respectively.

IC₅₀ Value: 1.2 nM (c-Abl); 307.6 nM(PDGFR β); 2662 nM (c-Kit) [1]

Target: c-Abl; c-Kit; PDGFR β

in vitro: HH-GV-678 can predominantly inhibit the autophosphorylation of Bcr-Abl in K562 cell. In higher concentration, HH-GV-678 can inhibit the phosphorylation of c-Kit in Mo7e cell and the phosphorylation of PDGFR in Swiss3T3 cell, however, HH-GV-678 has no or little effect on other tyrosine kinase including EGFR/KDR/c-Src and HER2 [1]. Flumatinib effectively overcame the drug resistance of certain KIT mutants with activation loop mutations (i.e., D820G, N822K, Y823D, and A829P) [2].

in vivo: The purpose of this study was to identify the metabolites of flumatinib in CML patients, with the aim of determining the main metabolic pathways of flumatinib in humans after oral administration. Ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry revealed 34 metabolites; 7 primary metabolites were confirmed by comparison with synthetic reference standards. The results show that the parent drug flumatinib was the main form recovered in human plasma, urine, and feces. The main metabolites of flumatinib in humans were the products of N-demethylation, N-oxidation, hydroxylation, and amide hydrolysis [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!